Top Story

Acid reflux medications may extend survival in HNSCC

December 26, 2014

Two types of antacid medications commonly used by patients with head and neck squamous cell carcinoma to reduce acid reflux may provide a survival benefit, according to study results.

“While we had suspicions that these medications might have favorable secondary effects, our study suggests that they improve OS after treatment,” Silvana M. Papagerakis, MD, PhD, of the department of otolaryngology — head and neck surgery at the University of Michigan, said in a press release.

Lee Schwartzberg FDA approvals

FDA approves Granix injection for self-administration in patients with severe neutropenia

December 26, 2014
The FDA has approved a self-administered injection of the leukocyte growth factor filgrastim for patients with nonmyeloid malignancies, allowing more flexibility for…
In the Journals

Changes in nevi were poor predictors of melanoma in children

December 26, 2014
Monitoring changes in nevi may not be a useful approach to melanoma detection in children and may lead to unnecessary biopsies in this population, according to recent…
FDA News

FDA recommends policy change allowing blood donations from MSM

December 26, 2014
The FDA recently recommended that men who have sex with men be allowed to donate blood, provided that their last sexual contact was at least one year ago.Based on a…
Meeting News CoveragePerspective

Rituximab maintenance prolonged EFS, PFS in young patients with mantle cell lymphoma

December 26, 2014
SAN FRANCISCO — Rituximab maintenance after autologous hematopoietic stem cell transplantation was associated with prolonged EFS and PFS compared with a…
More News Headlines »
Hot melanoma

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
Vosaroxin combination demonstrated improved survival in AML

Vosaroxin combination demonstrated improved survival in AML

December 20, 2014
SAN FRANCISCO — Farhad Ravandi, MD, professor of medicine in the department of leukemia at The University of…
More »
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »